Sinopharm vaccine - China approves clinical trials of Sinopharm's Omicron
China approves clinical trials of Sinopharm's Omicron
Peru study finds Sinopharm COVID vaccine 50.4% effective against infections
Sinopharm's Omicron
Omicron
Peru study finds Sinopharm COVID vaccine 50.4% effective against infections
Sinopharm's Omicron
China approves clinical trials of Sinopharm's Omicron
China approves clinical trials of Sinopharm's Omicron
China approves clinical trials of Sinopharm's Omicron
All the participants get 2 shots at either 3- or 4-week intervals that have generated neutralizing antibodies, measuring the vaccine's ability to stimulate a specific immune response to the coronavirus.
In February 2021, received the first 100,000 doses of 400,000 doses.
In April 2021, received a donation of 90,000 doses from China after granting emergency use authorization on 2 March.
- Related articles
2022 qa1.fuse.tv